XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill
3 Months Ended
Mar. 31, 2021
Goodwill
NOTE 6 – Goodwill:
The changes in the carrying amount of goodwill for the period ended March 31, 2021 were as follows:
 
    
North America
    
Europe
   
International
Markets
   
Other
    
Total
 
    
(U.S. $ in millions)
        
Balance as of December 31, 2020 (1)
   $ 6,473      $ 9,102     $ 2,362     $ 2,687      $ 20,624  
Changes during the period:
                                          
Translation differences
     4        (312     (14              (322
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
Balance as of March 31, 2021 (1)
   $ 6,477      $ 8,790     $ 2,348     $ 2,687      $ 20,302  
    
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
 
(1)
Accumulated goodwill impairment as of March 31, 2021 and December 31, 2020 was approximately $25.6 billion.
Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva’s production and sale of APIs to third parties (“Teva API”) and an
out-licensing
platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. The Teva API and Medis reporting units are included under “Other” in the above table. See note 15 for additional segment information.
Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva’s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (“WACC”), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva’s assumptions, Teva may recognize an impairment of goodwill allocated to these reporting units in the future.
During the first quarter of 2021, management assessed developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount.
Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of March 31, 2021 and, therefore, no quantitative assessment was performed.
 
Following the goodwill impairment charge recorded in the third quarter of 2020 in the North America reporting unit, the carrying value of the North America reporting unit equaled its fair value as of September 30, 2020. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to the North America reporting unit in the future.
The other reporting units all have fair value in excess of
 
10
%
over their book values as of March 31, 2021.